News
China’s National Medical Products Administration (NMPA) has approved four new drugs developed by local biopharma companies, ...
Regeneron, playing catch up with J&J and Pfizer, wins FDA approval for Lynozyfic in multiple myeloma
Another BCMA-targeted agent has arrived for the treatment of multiple myeloma. | After a delay, Regeneron’s BCMA-directed ...
Just days after President Donald Trump was elected in November, AstraZeneca unvei | AstraZeneca CEO Pascal Soriot is plotting ...
After taking aim at the United States’ vaccine safety reporting system earlier this year, Robert F. Kennedy Jr. | After ...
Despite the popularity of generic and biosimilar drugs in Europe—the latter of which have struggled to catch on in the ...
As Gilead Sciences gets underway with the key launch of its twice-yearly pre-exposure prophylaxis (PrEP) HIV med, the company ...
As Dry Eye Awareness Month kicks off, Bausch + Lomb is rolling out a new campaign to improve education about the condition. | ...
Thanks to his trusty Dexcom continuous glucose monitor (CGM), former boy band star Lance Bass is saying “bye bye bye” to ...
Despite the slow trickle of updates on President Donald Trump’s proposed pharmaceutical import tariffs, drugmakers have ...
A new survey from Takeda due to be presented at the ESMO Gastrointestinal Cancers Congress in Spain this week highlights ...
Unicycive Therapeutics has hit a bump on the road in its mission to bring its hyperphosphatemia treatment candidate to ...
The FDA’s regular communications based on reports from its drug safety report database don’t always rattle investors’ cages. | In a quarterly update, the FDA said it’s evaluating the need for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results